FDA Drug AMD3100 Unlocks Immune Attack on Rare Liver Cancer in Young Adults

Fibrolamellar carcinoma is a rare, aggressive liver cancer with no cure that primarily strikes children and young adults. It accounts for roughly 2% of liver cancer cases and is typically diagnosed late, leaving patients with few options. A new study published in Gastroenterology now reveals why standard immunotherapy has failed this group — and how an existing FDA-approved drug might change that.

Researchers from Cornell University and the University of Washington identified a process called T-cell exclusion as the central problem. Fibrolamellar tumors actively redirect immune T cells away from the cancer itself, trapping them in nearby fibrous tissue. Without T cells penetrating the tumor, immune checkpoint inhibitors — therapies designed to activate T cells against cancer — have nothing to work with. The cancer essentially hides from the immune system.

To uncover this mechanism, the team used single-nucleus transcriptomics, a cutting-edge technique that reads which genes are active in individual cells within tumor tissue. This gave researchers an unprecedented map of the tumor microenvironment and the cellular interactions occurring inside it — detail that was previously impossible to obtain in this rare cancer.

The key discovery was that AMD3100, already FDA-approved for mobilizing stem cells in bone marrow disorders, disrupts the tumor's ability to trap T cells. In tumor samples, the drug freed immune cells to infiltrate the cancer, significantly improving the effectiveness of immunotherapy. This suggests a potential combination treatment: AMD3100 alongside immune checkpoint inhibitors.

Important caveats apply. This research was conducted in tumor tissue samples, not in live patients, so clinical trials will be needed to confirm safety and efficacy in humans. The drug also may not be sufficient alone. Still, the mechanistic insight into T-cell exclusion represents a meaningful scientific advance for a cancer that has historically been untreatable, and it opens a credible new research direction for rare liver cancers.